--- title: "Ginkgo Bioworks | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 19.47 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285611221.md" datetime: "2026-05-07T20:22:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285611221.md) - [en](https://longbridge.com/en/news/285611221.md) - [zh-HK](https://longbridge.com/zh-HK/news/285611221.md) --- # Ginkgo Bioworks | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 19.47 M Revenue: As of FY2026 Q1, the actual value is USD 19.47 M, missing the estimate of USD 42.96 M. EPS: As of FY2026 Q1, the actual value is USD -1.39, missing the estimate of USD -1.34. EBIT: As of FY2026 Q1, the actual value is USD -79.74 M. Ginkgo Bioworks Holdings, Inc. issued a press release on May 7, 2026, announcing its financial results for the first quarter ended March 31, 2026. The company’s Biosecurity business was divested on April 3, 2026, and its financial results are now presented as a single reporting segment, with prior periods retrospectively recast . #### Revenue First quarter 2026 revenue was $19 million, marking a 49% decrease from $38 million in the comparable prior year period . Excluding a $7 million non-cash deferred revenue release in Q1 2025, first quarter 2026 revenue of $19 million was down 37% from $31 million in the comparable prior year period, primarily due to ongoing program rationalization as part of restructuring activities . Total revenue for Q1 2026 was $19,474 thousand, compared to $38,230 thousand for Q1 2025 . #### Net Loss GAAP net loss from continuing operations for the first quarter 2026 was - $76 million, an improvement from - $83 million in the comparable prior year period . The net loss from continuing operations was - $76,059 thousand for Q1 2026, compared to - $83,310 thousand for Q1 2025 . Net loss from discontinued operations was - $6,528 thousand for Q1 2026, compared to - $7,647 thousand for Q1 2025 . The total net loss was - $82,587 thousand for Q1 2026, compared to - $90,957 thousand for Q1 2025 . #### Adjusted EBITDA Adjusted EBITDA for the first quarter 2026 was - $42 million, an improvement from - $44 million in the comparable prior year period . The reported Adjusted EBITDA was - $42,255 thousand for Q1 2026, compared to - $44,242 thousand for Q1 2025 . #### Operational Expenses Total operating expenses for Q1 2026 were $90,848 thousand, down from $119,202 thousand for Q1 2025 . Cost of other revenue was $3,098 thousand for Q1 2026, compared to $4,090 thousand for Q1 2025 . Research and development expenses were $49,920 thousand for Q1 2026, compared to $70,923 thousand for Q1 2025 . General and administrative expenses were $37,830 thousand for Q1 2026, compared to $39,723 thousand for Q1 2025 . Restructuring charges were $0 for Q1 2026, compared to $4,466 thousand for Q1 2025 . Loss from operations was - $71,374 thousand for Q1 2026, compared to - $80,972 thousand for Q1 2025 . #### Cash and Marketable Securities Cash, cash equivalents and marketable securities balance as of March 31, 2026, was $373 million . Specifically, cash and cash equivalents were $143,864 thousand as of March 31, 2026, down from $167,202 thousand as of December 31, 2025 . Marketable securities were $229,592 thousand as of March 31, 2026, down from $255,418 thousand as of December 31, 2025 . #### Cash Flow Net cash used in operating activities from continuing operations was - $46,433 thousand for Q1 2026, compared to - $42,749 thousand for Q1 2025 . Net cash used in operating activities from discontinued operations was - $253 thousand for Q1 2026, compared to - $8,772 thousand for Q1 2025 . Total net cash used in operating activities was - $46,686 thousand for Q1 2026, compared to - $51,521 thousand for Q1 2025 . Net cash provided by investing activities was $23,132 thousand for Q1 2026, compared to net cash used of - $198,684 thousand for Q1 2025 . Net cash used in financing activities was - $19 thousand for Q1 2026, compared to - $207 thousand for Q1 2025 . Net decrease in cash, cash equivalents and restricted cash was - $23,702 thousand for Q1 2026, compared to - $250,338 thousand for Q1 2025 . Cash, cash equivalents and restricted cash at the end of the period were $188,669 thousand for Q1 2026, compared to $355,405 thousand for Q1 2025 . #### Other Financial Metrics - Stock-based compensation was $15,853 thousand for Q1 2026, compared to $17,386 thousand for Q1 2025 . - Depreciation and amortization was $12,799 thousand for Q1 2026, compared to $14,822 thousand for Q1 2025 . - Loss on investments was - $1,214 thousand for Q1 2026, compared to - $3,693 thousand for Q1 2025 . - Interest income, net, was $3,596 thousand for Q1 2026, compared to $6,081 thousand for Q1 2025 . - Income tax benefit was - $80 thousand for Q1 2026, compared to an expense of $88 thousand for Q1 2025 . #### Balance Sheet Highlights - Total current assets were $409,955 thousand as of March 31, 2026, compared to $471,838 thousand as of December 31, 2025 . - Total assets were $1,033,075 thousand as of March 31, 2026, compared to $1,119,696 thousand as of December 31, 2025 . - Total current liabilities were $79,595 thousand as of March 31, 2026, compared to $95,970 thousand as of December 31, 2025 . - Total liabilities were $589,922 thousand as of March 31, 2026, compared to $611,106 thousand as of December 31, 2025 . - Total stockholders’ equity was $443,153 thousand as of March 31, 2026, compared to $508,590 thousand as of December 31, 2025 . #### Outlook Ginkgo Bioworks Holdings, Inc. reaffirms its expected total cash burn for the full year 2026 to be between - $150 million and - $125 million . The company aims to double the size of its Nebula autonomous lab in 2026 . Its Cloud Lab, Datapoints, and Solutions offerings are generating revenue and accelerating the development of the autonomous lab . ### Related Stocks - [DNA.US](https://longbridge.com/en/quote/DNA.US.md) ## Related News & Research - [Ginkgo Bioworks to host Q2 2026 results presentation and Q&A session](https://longbridge.com/en/news/294412649.md) - [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md) - [Amneal Q2 revenue beats on specialty segment growth](https://longbridge.com/en/news/294342815.md) - [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md) - [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)